DCF — ESKENAZI HEALTH
Enterprise Value: $-497.3M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-497.3M
Enterprise Value
$-166.4M
PV of Cash Flows
$-331.0M
PV of Terminal Value
$-533.1M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $579.2M | $-26.1M | -5.0% | $-50.6M | $-46.0M |
| Year 2 | $596.6M | $-20.9M | -4.0% | $-46.1M | $-38.1M |
| Year 3 | $614.5M | $-15.4M | -3.0% | $-41.4M | $-31.1M |
| Year 4 | $632.9M | $-12.7M | -2.0% | $-39.5M | $-26.9M |
| Year 5 | $651.9M | $-11.4M | -2.0% | $-39.0M | $-24.2M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-497.3M. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$562.3M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.050000000266740986
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5